Interstitial transfer factor as adjuvant immunotherapy for experimental glioma
Glioblastoma multiform (GBM) is the most common tumour of the central nervous system in humans. Unfortunately its prognosis is poor and because of the lack of efficacious therapies, immunotherapy is a potential treatment. Transfer factors (TF) are low molecular weight dialysable products extracted from immune cells which transmit the ability to express delayed-type hypersensitivity and cell mediated immunity from sensitized donors to nonimmnune recipients. In this study, we determined the efficacy of TF as immunotherapy to treat experimental glioblastoma. We used TF obtained from immunized swine. We evaluated different doses of intratumoral TF (product of 4x10(6), 8x10(5) and 1.6x10(5) cells). The best dose (product of 4x10(6) cells) of TF was also combined with carmustine for experimental therapy in rats with C6 malignant glioma. Modifications in peripheral blood T lymphocyte counts ( CD2+, CD4+, CD8+ and NK) were evaluated by flow cytometry. Cytokine expression in the tumour was assessed by RT-PCR and apoptosis was evaluated using the sub G0 method. Intratumoral TF reduced significantly the tumour size, and increased CD2+, CD4+, CD8+ and NK cell counts, it also increased the percentage of apoptotic tumour cells and the percentage of tumour tissue expressing Th1 cytokines. We observed an additive antitumoral effect when TF was combined with chemotherapy.
Available from: Atanas Arnaudov
- "Cancer There are about 100 reports on the effect of TF on cancer. Pineda et al.  observed that treating rats that have C6 malignant glioma with swine TF preparation significantly reduces the tumour size and increases the CD2C, CD4C, CD8C and natural killer cell counts. It also increases the percentage of apoptotic tumour cells and the percentage of tumour tissue expressing Th1 cytokines. "
Biotechnology & Biotechnological Equipment 07/2015; DOI:10.1080/13102818.2015.1060136 · 0.30 Impact Factor
Available from: María C Jiménez-Martínez
- "Immunomodulation by Transferon® has been demon‐ strated by restoration of iNOS expression in a mouse model of tuberculosis, provoking inhibition of bacterial proliferation and significant increase of DTH  Transferon® also in‐ duces mRNA expression and IFN-γ secretion in peripheral blood mononuclear cells (PBMC) in animals with experimental glioma when compared with non-treated animals.  Due to Transferon® induces a Th1 response a clinical study comparing acyclovir treatment and Transferon® during human herpes virus infection was conducted; in that study patients treated with Transferon® had low incidence of clinical complications, better pain control, and also IFN-g was significant increased in serum when compared with patients treated on‐ ly with acyclovir.  Then, our group conducted a second clinical trial to evaluate immu‐ nological data and clinical outcome of patients with HSK treated with acyclovir or acyclovir and Transferon® as adjuvant therapy in patients with herpetic keratitis. "
[Show abstract] [Hide abstract]
ABSTRACT: The ocular surface is a functional unit mainly formed by the conjunctival and corneal epithelium (structural component), and tear film (soluble component). Microorganisms and environmental allergens can interact with the tear film, reach the structural component and generate an immune response against them. Understanding the cellular and soluble mediators that are involved in these inflammatory responses not only helps in understanding the mechanisms of current treatments, but also is needed to identification and development of new therapeutics targets. The aim of this review was to investigate the novel and developing therapies, with special emphasis in immunomodulatory drugs/molecules that could have some clinical indication in the treatment of infectious and allergic conjunctivitis in few years.
Common Eye Infections, Edited by Imtiaz A. Chaudhry, 05/2013: chapter Treatments in Infectious and Allergic Conjunctivitis: Is Immunomodulation the Future?: pages 45-60; InTech., ISBN: 978-953-51-0926-6
Available from: Emília Dvorožňáková
- "Similar results were recorded in murine tuberculosis treated with TF and antibiotics (Fabre et al. 2004). Th1-inducing effect of TF was also confirmed in anti-tumour immunotherapy (Pineda et al. 2005). The serum concentration of IL-5 in mice infected with E. multilocularis and treated with TF or combination of TF +ABZ in our study was inhibited till the end of the experiment. "
[Show abstract] [Hide abstract]
ABSTRACT: The effect of dialysable leucocyte extract (transfer factor TF) on immune response of mice infected with Echinococcus multilocularis and treated with albendazole (ABZ) was observed. TF administration increased the parasite-suppressed proliferative response of T and B lymphocytes of infected mice from weeks 8 to 12 or 14 post infection (p.i.), respectively, with the most stimulative effect after TF+ABZ therapy. The CD4 T cell presence in the spleen of infected mice with TF or TF+ABZ therapy was increased from weeks 6 to 12 or 14 p.i., respectively. The production of IFN-gamma (Th1 cytokine) after TF or TF+ABZ therapy was significantly higher from weeks 6 to 12 p.i., and during this time, the significantly inhibited IL-5 synthesis (Th2 cytokine) was detected, particularly after TF+ABZ therapy. The superoxide anion (O2-) production in peritoneal macrophages of infected mice treated with TF or TF+ABZ was stimulated from weeks 8 to 18 p.i. The immunomodulative effect of TF reduced the growth of larval cysts till week 14 p.i. with a comparable intensity to the anthelmintic drug ABZ. Combined therapy TF+ABZ resulted in the greatest parasite restriction and reduced the cyst development till the end of the experiment.
Parasitology Research 07/2009; 105(4):1067-76. DOI:10.1007/s00436-009-1520-z · 2.10 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.